ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Trading Up 0.5 %

ArriVent BioPharma stock opened at $19.60 on Thursday. The stock has a market cap of $666.71 million, a P/E ratio of -7.63 and a beta of 1.00. The stock has a 50 day moving average of $25.18 and a 200-day moving average of $26.82. ArriVent BioPharma has a 52 week low of $14.35 and a 52 week high of $36.37.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on AVBP shares. HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of ArriVent BioPharma in a research note on Friday, March 7th. Guggenheim started coverage on ArriVent BioPharma in a research note on Monday, March 10th. They set a “buy” rating and a $45.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $39.40.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.